DaCapo Rev Cycle

Midwest, USA

Short Summary

Revenue Cycle Management through a SaaS model. Market extends to medical billing companies and Electronic Medical Record vendors. Product has been live tested.

Highlights

  • Working product.
  • Positive feed back from test market.
  • Low overhead after initial mods to the software.
Please note: Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. This platform is targeted solely at investors who are sufficiently sophisticated to understand these risks and make their own investment decisions. This information has not been approved as a financial promotion, and you must carry out your own due diligence.

Overview

Target
US$2,000,000
Minimum
US$25,000
Investment Raised
N/A
Previous Rounds N/A
Stage MVP/Finished Product
Investor Role Any

Want to pitch on Angel Investment Network?

It’s easy to create a pitch using our online form. Your pitch can be in front of our 204,584 investors before you know it.

Create New Account
Already have an account?

Similar Projects

Featured
6% raised

Trillium Eye Care Pre-IPO

location_on South East, USA

Join this international health care group expand clinics in North America. Convertible Note pays 10% interest which converts into Stock pre-IPO. Company is targeting an IPO in the US at 5X Return to Investors.

US$ 1,500,000

Target

US$ 5,000

Min per Investor

Global Pro
0% raised

DownToDash App

location_on North East, USA

DownToDash is an app to make quality activity buddies. Users can post specific plans, for example, play Tennis on Thursday at 5 pm at McCarren Park and other users can join.

US$ 500,000

Target

US$ 50,000

Min per Investor

Pro
0% raised

TCI Healthcare Software

location_on South East, USA

Last year, 50% of all hospitals in the U.S. were penalized an average of $1.2 million each for failing to report patient satisfaction & quality of care data on time. TCI software products mitigate this exposure for as little as $395 p/mo.

US$ 500,000

Target

US$ 50,000

Min per Investor

load one similar proposal